<DOC>
	<DOCNO>NCT01086085</DOCNO>
	<brief_summary>This open-label , multi-center study evaluate effect quantitative HBsAg reduction peginterferon alfa-2a [ PEGASYS ] patient HBeAg positive chronic hepatitis B . Patients receive PEGASYS 180 mcg sc weekly . After 24 week treatment , rapid responder receive another 24 week treatment . After 24 week treatment , slow responder randomize another 24 72 week PEGASYS monotherapy , 72 week PEGASYS plus 36 week adefovir ( 10 mg , po daily , start week 29 PEGASYS treatment ) . The anticipated time study drug &gt; 2 year .</brief_summary>
	<brief_title>A Study Peginterferon Alfa-2a PEGASYS Patients With Chronic Hepatitis B Who Are HBeAg Positive</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Adult patient &gt; /=18 year age HBeAg positive chronic hepatitis B Compensated liver disease Patients previously receive treatment drug activity HBV within 6 month prior study start Antiviral , antineoplastic immunomodulatory treatment Coinfection active hepatitis A , hepatitis C , hepatitis D , HIV Evidence decompensated liver disease Chronic liver disease viral hepatitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>